Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 5, Supplement , Pages 96-106 , May 2009

Utility of Hyperbaric Oxygen in Treatment of Bisphosphonate-Related Osteonecrosis of the Jaws

  • John J. Freiberger, MD, MPH

      Affiliations

    • Assistant Professor of Anesthesiology, Center for Hyperbaric Medicine and Environmental Physiology, Duke University Medical Center, Durham, NC
    • Corresponding Author InformationAddress correspondence and reprint requests to Dr Freiberger: Department of Anesthesiology, Center for Hyperbaric Medicine and Environmental Physiology, Box 3823, Duke University Medical Center, Durham, NC 27710

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Novartis Pharmaceuticals Corporation is funding a randomized controlled trial of HBO for BP-associated osteonecrosis of the jaws. Dr Freiberger is the principal investigator.

PII: S0278-2391(08)01829-6

doi: 10.1016/j.joms.2008.12.003

Journal of Oral and Maxillofacial Surgery
Volume 67, Issue 5, Supplement , Pages 96-106 , May 2009

Article Tools

* Image Usage & Resolution